This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F13%3A33145239%21RIV14-MSM-15110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F13%3A33145239%21RIV14-MSM-15110___
rdf:type
n3:Vysledek skos:Concept
dcterms:description
Background Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise exposure and improve outcomes. We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. Background Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise exposure and improve outcomes. We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma.
dcterms:title
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
skos:prefLabel
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
skos:notation
RIV/61989592:15110/13:33145239!RIV14-MSM-15110___
n3:predkladatel
n7:orjk%3A15110
n5:aktivita
n12:I
n5:aktivity
I
n5:cisloPeriodika
12
n5:dodaniDat
n14:2014
n5:domaciTvurceVysledku
n18:5290791
n5:druhVysledku
n8:J
n5:duvernostUdaju
n16:S
n5:entitaPredkladatele
n13:predkladatel
n5:idSjednocenehoVysledku
62770
n5:idVysledku
RIV/61989592:15110/13:33145239
n5:jazykVysledku
n10:eng
n5:klicovaSlova
AG-013736; volunteers; antiangiogenesis; pharmacokinetics; efficacy; sorafenib; III trial; clinical-trials; solid tumors; interferon-alpha
n5:klicoveSlovo
n6:efficacy n6:interferon-alpha n6:pharmacokinetics n6:solid%20tumors n6:antiangiogenesis n6:AG-013736 n6:clinical-trials n6:volunteers n6:III%20trial n6:sorafenib
n5:kodStatuVydavatele
US - Spojené státy americké
n5:kontrolniKodProRIV
[854192C255E6]
n5:nazevZdroje
Lancet Oncology
n5:obor
n15:FD
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
12
n5:rokUplatneniVysledku
n14:2013
n5:svazekPeriodika
14
n5:tvurceVysledku
Grünwald, Viktor Pithavala, Yazdi Pavlov, Dmitri Fishman, Mayer Jonasch, Eric Arranz, Jose Bair, Angel Melichar, Bohuslav Rini, Brian Ueda, Takeshi Andrews, Glen Kim, Sinil
s:issn
1470-2045
s:numberOfPages
10
n19:doi
10.1016/S1470-2045(13)70464-9
n17:organizacniJednotka
15110